Prognostic and Predictive Value of Hematologic Parameters in Patients with Metastatic Renal Cell Carcinoma: Second Line Sunitinib Treatment Following IFN-alpha
Prognostic and Predictive Value of Hematologic Parameters in Patients with Metastatic Renal Cell Carcinoma: Second Line Sunitinib Treatment Following IFN-alpha
复制标题
DOI：
10.7314/apjcp.2013.14.3.2101
复制
发表时间：
2013-01-01
影响因子：
--
通讯作者：
Tarhan, Mustafa Oktay
中科院分区：
文献类型：
--
作者：
Dirican, Ahmet;Kucukzeybek, Yuksel;Tarhan, Mustafa Oktay
背景：长期生存是局部晚期和转移性肾细胞癌的一个问题。苹果酸舒尼替尼是一种口服多靶点酪氨酸激酶抑制剂，但舒尼替尼作为转移性肾细胞癌（mRCC）二线治疗的数据有限。外周血标志物的预后和预测价值已被证明是许多癌症。材料与方法：基于23例mRCC患者的回顾性数据，评估了干扰素α（IFN-α）治疗后舒尼替尼的疗效和安全性。在转移时记录血液学参数（中性粒细胞、淋巴细胞、血小板、平均血小板体积、中性粒细胞/淋巴细胞比率、血小板/淋巴细胞比率）。评估血液学参数是否是预后和预测因素。结果：中位无进展生存期（PFS）为16.5个月（95% CI：0-34.5）。中位总生存期（OS）为25.7个月（95% CI：10.8-40.0）。最常见的不良反应是中性粒细胞减少（52.2%）、口腔炎（26.1%）和手食综合征（26.1%）。中性粒细胞/淋巴细胞比值（NLR）> 3 vs NLR 3 vs NLR患者的PFS为3.13 vs 17.1个月
Background: Long-term survival is a problem with locally advanced and metastatic renal cell carcinomas. Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor, but data on sunitinib use as a second line treatment in metastatic renal cell carcinoma (mRCC) are limited. Prognostic and predictive value of peripheral blood markers has been shown for many cancers. Materials and Methods: Efficacy and safety profiles of sunitinib after interferon alpha (IFN-alpha) were evaluated based on retrospective data for 23 patients with mRCC. Hematological parameters (neutrophils, lymphocytes, platelets, mean platelet volume, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio) were recorded at the time of metastasis. It was evaluated whether hematological parameters were prognostic and predictive factors. Results: Median progression-free survival (PFS) time was 16.5 months (95% CI: 0-34.5). Median overall survival (OS) time was 25.7 months (95% CI: 10.8-40.0). Most common side effects were neutropenia (52.2%), stomatitis (26.1%) and hand-food syndrome (26.1%). PFS was found 3.13 vs 17.1 months in patients with neutrophil / lymphocyte ratio (NLR)> 3 vs NLR 3 vs NLR